Iqvia Holdings is a global leader in advancing healthcare by providing data analytics, technology, and consulting services to the pharmaceutical and life sciences industries. The company specializes in helping organizations improve their clinical trials, optimize research and development processes, and enhance patient engagement. By leveraging its extensive data assets and innovative technology platforms, Iqvia aids clients in making informed decisions that drive efficiency and effectiveness in bringing new therapies to market. Read More
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This development marks a significant step forward in streamlining the notoriously complex and expensive process of bringing new therapies to patients, promising substantial reductions in costs and a [...]
The stocks in this article are all trading near their 52-week highs.
This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial performance.
A company that generates cash isn’t automatically a winner.
Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Nvidia's (NASDAQ: NVDA) recent stock performance has been a whirlwind of soaring highs and sharp corrections, acting as a potent barometer for the broader Wall Street landscape as of November 11, 2025. The chip giant, a foundational pillar of the artificial intelligence (AI) revolution, has seen its immense market capitalization—
As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the drug development inputs & services industry, including IQVIA (NYSE:IQV) and its peers.
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence, announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective today.
Recent third-quarter (Q3) 2025 corporate earnings have painted a complex yet largely positive picture for North American equity markets. While robust performances from key sectors, particularly technology, have propelled major U.S. and Canadian indices to new heights, a closer look reveals a landscape of mixed results, with individual company
IQVIA's third quarter results reflected stable operational execution, with revenue and profit slightly ahead of Wall Street expectations. Management identified robust free cash flow generation and a healthy pipeline of clinical trial bookings as primary contributors to the quarter’s performance. CEO Ari Bousbib emphasized improvements in industry demand, noting that net bookings in the clinical segment grew 13% year over year, while the company’s backlog reached $32.4 billion. Bousbib credited disciplined working capital management and a more stable industry environment as key drivers behind the results.
Shares of clinical research company IQVIA (NYSE: IQV)
fell 2.5% in the afternoon session after TD Cowen downgraded its rating on the stock from Buy to Hold. The firm cited valuation concerns as the main reason for the change, noting that IQVIA's current stock price already reflected its growth outlook. Analysts also pointed to "generally subdued market conditions and margin pressures" as factors that limited the potential for further gains. While TD Cowen did raise its price target on the shares to $215 from $206, the downgrade signaled caution. The negative sentiment from this rating change appeared to outweigh a more positive view from Morgan Stanley, which maintained its Overweight rating and raised its price target on the same day.
Clinical research company IQVIA (NYSE: IQV) reported Q3 CY2025 results topping the market’s revenue expectations, with sales up 5.2% year on year to $4.1 billion. The company expects the full year’s revenue to be around $16.2 billion, close to analysts’ estimates. Its non-GAAP profit of $3 per share was 0.8% above analysts’ consensus estimates.
As of October 2025, Nvidia (NASDAQ: NVDA) stands on the precipice of a historic $5 trillion market valuation, a testament to its unparalleled dominance in the artificial intelligence (AI) and high-performance computing (HPC) sectors. This monumental achievement, which has seen its market capitalization soar past $4.5 trillion and, at
Clinical research company IQVIA (NYSE: IQV) reported revenue ahead of Wall Street’s expectations in Q3 CY2025, with sales up 5.2% year on year to $4.1 billion. The company expects the full year’s revenue to be around $16.2 billion, close to analysts’ estimates. Its non-GAAP profit of $3 per share was 0.8% above analysts’ consensus estimates.
IQVIA Q3 2025 earnings beat EPS estimates with $3.00 per share. Revenue grew 5.2% to $4.10B. The company reaffirmed its strong full-year 2025 guidance.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2025.
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand.
The result? Over the past six months, the industry’s 13.5% return has trailed the S&P 500 by 9.4 percentage points.
IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, announced today that Ari Bousbib, chairman and chief executive officer, will speak at the UBS Global Healthcare Conference on Tuesday, November 11, 2025 at 12:30 p.m. ET.
Shares of clinical research company IQVIA (NYSE: IQV)
jumped 3.6% in the afternoon session after Bank of America raised its price target on the company's shares to $230 from $215. The adjustment from the investment bank suggested a more positive outlook on the stock's potential value. This move occurred while the company maintained an average rating of 'buy' among analysts polled by FactSet. An increased price target can signal confidence in a company's future performance, which often attracts investor interest.
IQVIA has had an impressive run over the past six months as its shares have beaten the S&P 500 by 11.8%. The stock now trades at $200.20, marking a 39.8% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
The U.S. labor market is flashing clear signs of weakness as of October 2025, prompting a significant shift in the Federal Reserve's monetary policy. With unexpected job losses and a rising unemployment rate, investors are now betting heavily on continued interest rate cuts, shaping a complex narrative of market
